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 > COVID-19 is associated with a hypercoagulable state with 
increased VTE rate.
 > COVID-19 patients frequently have very high von Willebrand 
factor (vWF) and factor VIIIc levels that are comparable to 
those seen in ICU patients with severe sepsis.
 > Further studies are needed urgently to evaluate the use of 
vWF as a pragmatic measure to stratify thrombotic risk in 
COVID-19.
Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
causing coronavirus disease 2019 (COVID-19), has infected more 
than 12 million people and caused more than 500,000 deaths 
worldwide.1 It affects primarily the respiratory system, but can also 
involve the cardiovascular, gastrointestinal and haematological 
systems. Autopsy reports of COVID-19 cases have revealed alveolar 
exudative inflammation, epithelium proliferation, interstitial 
inflammation and hyaline membrane formation in the lungs. 
Pathological lesions were also seen in other organs such as heart, 
vessels, liver and kidney.2 The most characteristic finding in non-
survivors with COVID-19 was diffuse alveolar damage, which was 
accompanied by extensive microvascular thrombosis in lungs and 
extrapulmonary organs.3 Megakaryocytes have been identified 
within the small vessels and alveolar capillaries identified by CD61 
and vWF immunostains.4
The rate of venous thromboembolism (VTE) in critically ill 
hospitalised patients is 10%.5 However, early studies show that the 
incidence of VTE in patients with severe novel coronavirus pneumonia 
can be as high as 25%.6 Early case reports have described an 
association between COVID-19 and venous thrombo-embolic events.7 
Tang et al found that treatment with prophylactic heparin (lower 
molecular weight heparin or unfractionated heparin) was associated 
with a reduced 28-day mortality in severe COVID-19.8
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Background
COVID-19 infection is characterised, among other features, by a 
prothrombotic state with high rate of venous thromboembolism 
(VTE), D-dimer, and fibrinogen levels. Clinical observations 
have also highlighted that these patients have elevated von 
Willebrand factor (vWF) and factor VIIIc.
Methods
24 consecutive COVID-19 positive patients were selected from 
the intensive care unit (ICU) or the high acuity ward of Brighton 
and Sussex University Hospitals NHS Trust.
Results
The rate of VTE was 25% and mortality rate was 16.7%. 
Fibrinogen and D-Dimers were elevated, 7.9 (1.6) g/L and 2.4 
(2.02) ug/ml respectively. Factor VIIIc and von vWF antigen 
levels were both extremely elevated at 279 (148) u/dL and 350 
(131) % respectively, which are comparable to levels seen in 
ICU patients with severe sepsis. vWF levels were significantly 
higher in patients that died (p=0.017) and showed a positive 
correlation with age. There was a statistically significant 
association between COVID-19 disease and non-O blood group 
(p=0.02); 80% (4/5) of COVID-19 patients with VTE were blood 
group A.
Conclusion
Very high levels of vWF and factor VIIIc are common in 
COVID-19 patients, comparable to levels in severely septic 
non-COVID ICU patients. This could contribute to the 
hypercoagulable state and increased VTE rate in COVID-19. 
Further studies are needed to evaluate the use of vWF for 
stratifying thrombotic risk in COVID-19 and to determine if 
elevated vWF is contributing to disease pathogenesis.
KEYWORDS: von Willebrand factor, factor VIIIc, COVID-19, venous 
thromboembolism, blood group
DOI:10.7861/clinmed.2020-0346
 Clinical Medicine Publish Ahead of Print, published on July 21, 2020 as doi:10.7861/clinmed.2020-0346
 Copyright 2020 by Royal College of Physicians.
2© Royal College of Physicians 2020. All rights reserved.
Coagulopathy is a hallmark of severe COVID-19, with 71.4% 
of non-survivors showing features of disseminated intravascular 
coagulation (DIC) during their hospital stay.9 This is mainly 
characterised by a prothrombotic diathesis with high VTE 
rate, D-dimer, and fibrinogen levels.10 There are several studies 
investigating D-dimers in COVID-19. Patients with severe COVID-19 
had high D-dimer levels while those requiring ICU admission were 
shown to have even higher D-dimer levels,11 which was associated 
with development of acute respiratory distress syndrome (ARDS) 
and progression to death.12 A case-control study investigating VTE in 
COVID-19 patients showed that D-dimer was elevated in confirmed 
VTE cases and controls but higher levels were seen in confirmed 
VTE cases.13 A pooled analysis by Lippi et al confirmed that D-dimer 
levels are higher in patients with severe COVID-19. However, it also 
highlighted heterogeneity across studies.14 
Clinical observations from our hospital showed that a few critically 
unwell COVID-19 patients who developed VTE also had highly elevated 
levels of von Willebrand factor (vWF) and factor VIIIc. The aim of this 
study was to further explore markers of coagulopathy in patients with 
COVID-19 which could indicate or explain a tendency for VTE.
Methods
Patients
This study was carried out at the Brighton and Sussex University 
Hospitals NHS Trust. We identified 24 patients with COVID-19 who 
had undergone investigation for coagulopathy as part of their 
routine inpatient care. Included were consecutive patients who were 
admitted for active management of COVID-19 onto ITU, HDU 
and COVID wards of the hospital. Patients were admitted to the 
intensive care unit (ICU) or the high acuity ward and received 
standard care, according to the hospital’s COVID-19 guidelines. 
Data collected up to 1 May 2020 were analysed.
Materials
Deep-vein thrombosis was diagnosed with doppler ultrasound, 
pulmonary embolism was diagnosed with CT pulmonary angiogram 
and hepatic veno-occlusive disease was diagnosed with contrast 
enhanced CT abdomen. Scans were performed only if there was 
a clinical suspicion of thrombosis and were reported by consultant 
radiologists. Blood samples were collected in 0.109 M sodium citrate 
tubes. All haemostasis assays were performed using a STA-R® MAX 
2 coagulation analyser (Diagnostica Stago®, Asnières-sur-Seine, 
France). The PT, APTT, fibrinogen and D-dimer were determined in 
plasma immediately after a single centrifugation (2000 g for 10 
min). PT and APTT were measured using STA®-Neoplastine R and 
STA®-Cephascreen, respectively (Stago). Quantitative determination 
of fibrinogen level was determined via the Clauss method, using 
the STA®-Liquid Fib reagent (Stago). D-dimer was quantified by 
immunoturbidimetry using Liatest® D-Di PLUS reagent (Stago). 
Platelet-poor plasma (PPP) was then obtained by double centrifugation 
(2 x 2000 g for 10 min). PPP was frozen at – 80°C until use and thawed 
for 4 min in a 37°C water bath before the assays. FVIII activity was 
measured with a one-stage clotting assay using STA®-C.K. Prest and 
STA®-Immunodef VIII reagents (Stago), calibrated to normal human 
plasma. VWF:Ag was quantified by immunoturbidimetry using Liatest® 
vWF:Ag reagent (Stago). VWF:RCo activity was quantified with STA®-
VWF:RCo (Stago), by means of a turbidimetric method based on 
platelet aggregation in presence of ristocetin.
Statistics
Statistical analysis was performed using GraphPad software. 
Comparison between two non-normally distributed variables was 
performed by Mann-Whitney test. Logistic regression was used when 
assessing correlation between clinical parameters and dichotomous 
variables (eg death/alive, blood group O/non-O, presence of VTE/no 
VTE). P-value <0.05 was considered statistically significant.
Ethics
This work was carried out as a service evaluation. Data collection 
and analysis were anonymised and secure with password protection.
Results and discussion
The rate of VTE was 25% (6/24): pulmonary embolism (four 
patients), upper limb deep-vein thrombosis (one patient), hepatic 
veno-occlusive disease (one patient). Mortality rate was 16.7% 
(4/24) and 75% were admitted to ICU. Of those admitted to ICU, 
39% (7/18) were intubated and ventilated, while 61% (11/18) 
received level 1/level 2 care. The following results are expressed 
in median (IQR). The age of COVID-19 positive patients was 65 
(18) and they were predominately male (75%). The INR and 
APTT ratio were both within the normal range, 1.1 (0.1) and 1.3 
(0.3) respectively. Platelets were also within the normal range: 284 
(251) 109/L. Fibrinogen was elevated at 7.9 (1.6) g/L with an upper 
normal limit of 4.5 g/L. D-dimer were also increased 2.4 (2.02) ug/
ml with an upper normal limit of 0.5 ug/ml. Factor VIII and von 
Willebrand factor antigen were considerably high, 279 (148) u/dL 
and 350 (131) % respectively. 15 patients were also tested for anti-
phospholipid antibodies. Only two were positive for anti-cardiolipin 
IgM, while none were positive for anti-cardiolipin IgG or anti-B2 
glycoprotein IgG.
Overall the results support the case that COVID-19 causes 
significant coagulopathy, with greatly increased vWF and 
factor VIIIc levels. This may be a result of endothelial damage. 
An explanation for the markedly increased vWF levels in 
COVID-19 patients could be that SARS-CoV-2 enters cells via the 
transmembrane protein ACE2. ACE2 is expressed on the surface of 
alveolar epithelial cells, and arterial and venous endothelial cells.15 
The entry of the virus could contribute to inflammation and damage 
of endothelial cells causing release of prothrombotic mediators, 
primarily vWF from the Weibel–Palade storage bodies, and exposing 
underlying collagen to which vWF binds (Fig 1).
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Fig 1. Schematic representation of how SARS-CoV-2 entry damages 
the endothelium, which subsequently results in vWF release mediating 
platelet aggregation and adhesion.
3 © Royal College of Physicians 2020. All rights reserved.
COVID-19 rapid reports
Table 1: Clinical characteristics and laboratory parameters 
of patients with COVID-19 in our study and in the study by 
Helms et al16
Helms et al Our data
Number of patients 150 24
Age [median (IQR)] 63 (53–71) 65 (55–72)
Male [N (%)] 122 (81.3) 18 (75)
Platelet [median (IQR)] 200 (152–267) 284 (188–439)
APTT ratio [median (IQR)] 1.2 (1.1–1.3) 1.3 (1.1–1.4)
INR [median (IQR)] 1.12 (1.05–1.25) 1.1 (1.1–1.2)
D-dimer ug/ml  
[median (IQR)]
2.27 (1.16–20) 2.4 (1.5–3.5)
Fibrinogen g/L  
[median (IQR)]
6.99 (6.08–7.73) 7.9 (7.3–8.9)
Factor VIIIc u/dL (60-150) 
[median (IQR)]
341 (258–416) 279 (251–363)
Von Willebrand factor 
antigen % (50-140) 
[median (IQR)]
455 (350–521) 350 (302–433)
One patient in this series, with massive DVT and PE, and who 
exhibited extremely high vWF level 762u/dL, factor VIII 506% and 
RiCoF level >200, underwent more extensive analysis of coagulation 
parameters. This revealed raised factor IX 177%, protein C 133%, 
protein S 112% and reduced anti-thrombin level 74% (reference 
range 84– 19%). In addition, lupus anticoagulant testing was positive 
by DRVVT (correction 16.6%) and dilute APTT (correction 37.7%). 
Finally, and of particular interest, a reduced ADAMTS13 level of 49.7% 
(reference range 66–108) was seen, suggesting loss of the vWF 
cleaving protease that ordinarily degrades large vWF multimers and 
reduces its activity. We speculate that excess release of vWF seen in 
COVID-19 patients leads to depletion of ADAMTS13 and contributes 
to the prothrombotic state (Fig 1). Further studies are needed to 
measure ADAMT13 levels in a larger cohort of COVID-19 patients 
along with vWF multimer analysis to establish whether ultra-large 
multimers contribute to COVID-19 disease pathogenesis.
Helms et al recently published a multicenter prospective cohort 
study in France, assessing thrombotic risk in COVID-19 patients, which 
showed that vWF and VIIIc were considerably increased in COVID-19 
patients.16 Our study, although smaller, has patients with similar 
demographic characteristics and confirms their findings in a British 
hospital setting. Detailed comparison of the two studies is described 
below (Table 1). Interestingly, while Helms et al examined those 
admitted to ICU and ventilated, our results extend these high wWF 
levels to those who are receiving level 1 (general ward-based) and 
level 2 (high dependency) care. There was no statistically significant 
difference in vWF and factor VIIIc levels between ventilated versus 
non-ventilated patients. Panigada et al also reported that COVID-19 is 
characterised by hypercoagulability with a severe inflammatory state. 
Their results confirmed higher mean levels of vWf and factor VIIIc in 
their cohort, 529 U/dl and 297 U/dl respectively.17
It remains unclear whether this observed coagulopathy is the case 
for other infections, such as sepsis or viral pneumonias, as well. High 
levels of D-Dimers have been previously associated with 28-day 
mortality in patients presenting to the emergency department 
with sepsis.18 However, its prognostic value in sepsis has been 
questioned.19 Chen et al showed that patients with pneumococcal 
pneumonia were at higher risk for DVT and PE, which was highest 
during first 4 weeks but remained slightly elevated from 13 weeks to 
2 years after acute infection.20 We compared our results to Kremer 
et al, who investigated vWF and related parameters in severe 
sepsis and septic shock. Their results showed that the median VWF 
antigen (%) was significantly higher in patients (373) compared 
to controls (89) (P<0.001); however, this did not correlate with 
disease severity, organ dysfunction or outcome.21 Our results showed 
that the median vWF antigen was 342, which is very close to the 
vWF antigen present in acutely unwell patients with severe sepsis 
and septic shock. It is significantly higher than 89, which was the 
median vWF antigen measured in matched healthy controls by 
Kremer et al (Table 2). There are a few case reports on influenza and 
coagulopathy, but data on thrombotic microangiopathy is limited. 
Avnon et al reported that 25% of critically ill patients with influenza 
A/H1N1 had thrombotic events.22 Empirical systemic heparin 
anticoagulation in critically ill patients with H1N1 ARDS significantly 
reduced VTE incidence.23 Tsujii et al reported the case of a boy with 
heterozygous protein S-deficiency, who was diagnosed with H1N1 
influenza, whose plasma VWF was significantly elevated (299% 
of normal).24 Another case report by Akiyama et al also described 
18-year-old female with H1N1 influenza whose plasma levels of 
VWF were remarkably raised (191% of normal).25 Lastly, varicella 
zoster virus has been linked to transient protein C and S deficiency, 
which was associated with thrombotic complications in children.26














































Fig 2. Percentage (%) von Willebrand antigen in patients that have 
passed away or remained alive at the end of the study. 














































Fig 3. Scatter plot of vWF antigen (%) in relation to age in COVID-19 
patients.
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Further analysis of our data showed that median vWF levels (%) 
were significantly higher in patients that died (477) compared to 
the ones that remained alive (335) (p=0.015). However, this needs 
further evaluation as the patients were not randomly selected 
and most remained alive by the end of the study (n=18) (Fig 2). 
However, we did observe a positive correlation between age and 
vWF level with older COVID-19 patients tending to have higher vWF 
levels with an approximate linear regression formula of vWF = (4 x 
age) + 100 (Fig 3). This may contribute to the observed increased 
COVID-19 mortality rate in older individuals. Evaluation is needed 
to establish whether ethnic variations in vWF levels contribute to the 
different susceptibility rates amongst specific ethnic groups that is 
emerging in the current pandemic, although our data did not allow 
us to address this question.
Lastly, we investigated ABO blood group given the known 
tendency for individuals with non-O blood to have higher vWF levels 
than individuals with group O blood. Five patients were excluded as 
the blood group was unknown. 68% of patients had non-O blood 
group (11/19 group A and 2/19 group B) compared with 32% who 
had O blood group (6/19 group). Using NHS Blood Transfusion 
data for the expected frequency of non-O blood group (52%) 
and O blood group (48%) for the UK population, this difference is 
statistically significant (p=0.02, Chi-square test). We also observed 
that 80% (4/5) of the patients who developed VTE were group 
A, while 20% (1/5) were group O (p=0.22). Published literature 
suggests that patients with blood group A have higher rates of 
severe COVID-19 and mortality.27
Conclusion
This study provides a valuable insight into the coagulopathy that 
characterises COVID-19. D-dimers, fibrinogen, vWF factor and  
factor VIIIc are generally very high in COVID-19 patients and 
comparable to levels seen in severely unwell septic patients on ICU. 
This could be contributing to the hypercoagulable state with increased 
VTE rate, although we recognise that the correlation with elevated 
vWF levls does not necessarily imply mechanistic causation. We also 
demonstrate a tendency for more severe COVID-19 disease and 
VTE in patients with non-O blood group but recognise again that our 
data contains limited number of patients and therefore await other 
studies to confirm this result. Finally, we propose that vWF might serve 
as a simple prognostic measure of thrombotic risk in COVID-19 and 
potentially a significant contributor to disease pathogenesis. 
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